Under-fire Dutch medical device maker Philips said Wednesday extensive testing on its recalled respirator devices showed they were "within safety limits" for use, but that a final verdict rests with global regulatory authorities.
Dec 21, 2022
0
2
In the competition between brand name pharmaceuticals and their generic counterparts, drug companies use patent gamesmanship to their advantage, one West Virginia University patent expert said.
Dec 19, 2022
0
3
More biosimilars have been marketed in Germany and Switzerland than in the United States, but uptake has increased over time in all countries, according to a study published online Dec. 2 in JAMA Network Open.
Dec 2, 2022
0
3
For nearly 10 years, Stacie Dusetzina, Ph.D., a Vanderbilt University professor of Health Policy and Ingram Professor of Cancer Research, has focused her research on one core policy issue that has been of interest to lawmakers ...
Nov 3, 2022
0
2
In the first known study of its type, an international team of researchers evaluated whether high research and development (R&D) costs explain high drug prices in the United States.
Sep 26, 2022
1
82
The Inflation Reduction Act contains provisions that are expected to lower drug costs for millions of Americans by allowing Medicare to negotiate some drug prices and by limiting the amount of out-of-pocket drug costs for ...
Aug 9, 2022
0
2
Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National ...
Jul 28, 2022
0
14
In a new study from the University of Bergen (UiB), confidential drug prices have been used to evaluate coverage decisions for new drugs in Norway.
Jun 29, 2022
0
4
Prescription drugs are a major source of expenditure for patients in Ireland. High prices can lead to cost-related non-adherence and adverse health outcomes. Researchers at Trinity College and RCSI University of Medicine ...
May 31, 2022
0
3
Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer's drug whose benefits have been widely questioned, a major development in the nation's tug-of-war over the fair value of new medicines that offer ...
Jan 11, 2022
0
16
